NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma

NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma

Descartes-25 in Relapsed/Refractory Multiple Myeloma

This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.

Sponsor

Cartesian Therapeutics

---

ClinicalTrials.gov Identifier: NCT05113342

Official Title: Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma

First Posted: November 9, 2021

Click here to see details on ClinicalTrials.gov

---